includes:study
If GLP1 is so great, why don't people stick with it?
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
chemical:tirzepatide
category:news
A glowing endorsement of GLP1s by cardiologists
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
category:news
Preserving muscle: GLP1s with Bimagrumab
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
category:news
A challenge to Eli Lilly's Tirzepatide patent
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
company:eli-lilly
Eli Lilly's big Summer 2025 update
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
research
Semaglutide vs Tirzepatide (Clinical trial)
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
malady:addiction
GLP1s vs. Addiction, a quick review
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.
category:news
Hims pivots to branded Tirzepatide, generic Liraglutide
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
category:side-effects
Pancreatitis and Gallstones after massive weight loss
We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s
category:benefits
Zepbound coverage for Sleep Apnea gets Agency approval
Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.
category:factsheet
Patent expirations for GLP1 Receptor Agonists
How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.
category:news
FDA reconsidering Tirzepatide shortage list removal
After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.